Caladrius Biosciences   Report issue

For profit Phase 2 Phase 3
Founded: Irvine CA United States (2005)

Organization Overview

First Clinical Trial
2005
NCT00012064
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Caladrius Biosciences, Inc. | Chief Medical Officer, Caladrius Biosciences | China Cell Technology Ltd | China Cell Technology Ltd. licensed CBMG to conduct the clinical trial as the sponsor in China | NeoStem Oncology, LLC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atherosclerosis (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Central Nervous System Neoplasms (Phase 2)

Coronary Artery Disease (Phase 2)

Coronary Disease (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Glioblastoma (Phase 2)

Infarction (Phase 2)

Ischemia (Phase 2)

Kidney Neoplasms (Phase 2)

Melanoma (Phase 3)

Microvascular Angina (Phase 2)

Myocardial Infarction (Phase 2)

Myocardial Ischemia (Phase 2)

Nervous System Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

ST Elevation Myocardial Infarction (Phase 2)

Thromboangiitis Obliterans (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial APIs: 16